UPDATE: Viridian Therapeutics' REVEAL-1 Study Shows Elegrobart Efficacy; Q4W CAS And Q8W Diplopia Endpoints Miss Statistical Significance; Shares Trading Lower, Future Trial Dependence May Concern Investors